GlassScriptPhysician profile
Todd K Howard
NPI 1154351765
$351.01
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2020: $93.02 · 2021: $92.65 · 2022: $44.67.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $121.63 | 2020-2022 | |
| Ethicon US, LLC | $75.51 | 2019-2021 | |
| Cvrx, INC. | $23.68 | 2021 | |
| Integra Lifesciences Corporation | $22.38 | 2019 | |
| Abbvie INC. | $20.90 | 2021 | |
| Tetraphase Pharmaceuticals, INC. | $19.39 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.06 | 2020 | |
| Teleflex LLC | $14.73 | 2021 | |
| Aesculap, INC. | $13.79 | 2019 | |
| Cook Medical LLC | $11.69 | 2019 | |
| Tela Bio, INC. | $11.25 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Howard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.